L
Lumena Pharmaceuticals
Shire: A Global Innovator in Specialty Biopharmaceuticals
About Lumena Pharmaceuticals
Lumena Pharmaceuticals, Inc. operated as a biopharmaceutical firm with a clear focus on developing treatments for rare and severe liver diseases. Founded in 2011 by Pappas Ventures, the company was established to address cholestatic liver diseases, which are characterized by impaired bile acid flow that leads to progressive liver damage. The leadership team included President and CEO Mike Grey, a venture partner at Pappas Ventures with prior experience as CEO of SGX Pharmaceuticals, which was acquired by Eli Lilly & Co. in 2008. The management team's extensive experience was a key factor in advancing the company's clinical programs.
The company's core business revolved around its two main product candidates, LUM001 and LUM002. Both were orally administered inhibitors of the apical sodium-dependent bile acid transporter (ASBT), a protein responsible for recycling bile acids from the intestine back to the liver. By blocking this transporter, the drugs aimed to reduce the absorption of bile acids, thereby lowering their concentration in the liver and bloodstream. This mechanism was intended to slow disease progression, improve liver function, and alleviate debilitating symptoms like severe itching (pruritus) for patients with these conditions. Lumena's target market consisted of pediatric and adult patients suffering from rare cholestatic liver diseases such as Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Additionally, LUM002 was being developed for nonalcoholic steatohepatitis (NASH), a more common metabolic disorder.
Lumena's journey was marked by significant financial and clinical milestones. The company secured $23 million in a Series A financing round in 2013, followed by a $45 million Series B round in 2014 led by New Enterprise Associates. These funds were crucial for advancing the clinical development of its lead candidates. In a strategic move that highlighted the potential of its pipeline, Lumena Pharmaceuticals was acquired by Shire plc in May 2014 for an upfront payment of $260 million, with additional near-term milestone payments. This acquisition was a strategic fit for Shire, strengthening its rare disease portfolio and complementing its existing gastrointestinal business. The deal provided Shire with LUM001, then in Phase 2 trials for four orphan indications, and LUM002, which was ready to enter Phase 2. The acquisition was seen as a positive outcome for investors and, most importantly, for patients with rare cholestatic liver diseases.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 60.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, Brokerage, Disease, Auction, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2014 | $260M | $260M | Shire | — |
| SERIES BOther financing | Mar 2014 | $45M | $180M | Pappas Capital · Alta Partners · RiverVest Venture Partners · RA Capital Management | — |
Growth signals
Latest recorded traffic for Lumena Pharmaceuticals is 1.1K monthly website visits, up 74.6% over the last three months. Lumena Pharmaceuticals's team declined 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Lumena Pharmaceuticals in the San Diego ecosystem
The Lumena Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Pappas Capital
Alta Partners
RiverVest Venture Partners
NEA
RA Capital Management
Other known investors1 additional known investor
Shire
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lumena Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lumena Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









